NCT06385262 - TOP 2301: Neoadjuvant Chemo for NSCLC | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2029

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Alirocumab

300 mg subcutaneously every 4 weeks prior to surgery

DRUG

Cemiplimab

350mg IV every 3 weeks prior to surgery

DRUG

Chemotherapy

Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery

Trial Locations (1)

RECRUITING

Duke University, Durham